CDNA — CareDx, Inc

CareDx, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Increased 39% to $118 million.
• Testing Volume: Up 17% to 54,900 tests.
• Testing Services Revenue: Grew 48% to $91 million, averaging $16.60 per test.
• Patient and Digital Solutions Revenue: Increased 33% to $16 million.
• Lab Products Revenue: Declined 4% to $10 million.
• Non-GAAP Gross Margins: Improved to 73%.
• GAAP Net Income: $3 million, or $0.05 per share.
• Adjusted EBITDA: Increased over 300% to $19 million.
• Cash Collections: Rose 52% to $121 million; cash flow from operations was $4 million for the quarter.
• Cash Position: Ended the quarter with $198 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Divestiture of Lab Products: Announced on April 15, aimed at streamlining operations and focusing on precision medicine testing services. Expected to close by Q3 2026, providing $170 million in cash.
• Acquisition of Navaris: Announced during the call, targeting solid tumor minimal residual disease (MRD) with a differentiated platform. Navaris has performed over 130,000 tests and is covered for approximately 100 million lives.
• Growth Strategy: Focused on expanding leadership in precision medicine testing, with pipeline initiatives including Alaheme for cell therapy, AlloSure for liver transplantation, and HistoMap kidney.
• Clinical Data Presentation: CareDx's testing services were featured in over 50 abstracts at a major transplant meeting, reinforcing the clinical relevance of their molecular monitoring.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $447 million to $465 million, representing a 20% year-over-year increase.
• Adjusted EBITDA Guidance: Estimated between $43 million and $57 million, a 58% increase year-over-year.
• Testing Volume Expectations: Projected between 224,000 and 229,000 tests for the year, a 13% increase year-over-year.
• Revenue per Test: Expected to increase to $14.60 by year-end, with a 10% year-over-year growth.

4. Bad News, Challenges, or Points of Concern

• Lab Products Decline: Revenue from the Lab Products segment decreased, indicating potential challenges in that area.
• Transplant Procedure Volumes: Overall transplant volumes remain sluggish, which could impact future growth rates despite CareDx's ability to grow testing volumes.
• Market Competition: Concerns about maintaining competitive advantages in a rapidly evolving market, especially with the introduction of Navaris and its differentiated technology.
• Regulatory Risks: The anticipated Local Coverage Determination (LCD) for transplant testing remains uncertain, with expectations set for mid-2026.

5. Notable Q&A Insights

• Market Accessibility for Navaris: The existing infrastructure allows for immediate access to a $1.5 billion MRD market, with no new channels needed for growth.
• Digital Solutions Adoption: 70% of transplant centers utilize at least one CareDx digital solution, indicating strong integration into clinical workflows.
• Navaris Growth Potential: Expected growth rate of 30% to 40% annually, driven by volume rather than average selling price (ASP).
• Operational Learnings: CareDx plans to leverage its experience in workflow optimization and provider education from the transplant business to enhance Navaris's market penetration.

This summary encapsulates the key points from CareDx's Q1 2026 earnings call, highlighting financial performance, strategic initiatives, future outlook, and areas of concern.